NKSquared Backs Biopeak in Follow-On Round
Longevity-focused healthtech startup Biopeak has raised $2.7 million in a follow-on funding round led by NKSquared, the venture capital firm founded by Nikhil Kamath.
This marks Kamath’s second investment in the company, following his earlier $1.43 million infusion in August 2024. The latest round reinforces NKSquared’s growing interest in preventive healthcare and longevity-led health models.
Capital to Fund Expansion and Technology
Biopeak plans to deploy the fresh capital to scale its operations across multiple fronts. Key priorities include opening a new flagship clinic in Bengaluru, expanding its core team, and strengthening its specialist clinics and diagnostic capabilities.
The company also intends to increase investment in its proprietary artificial intelligence tools, research infrastructure, and clinical programmes, as it deepens its focus on long-term health optimisation rather than episodic care.
A Longevity-First Health Model
Founded by Rishi Pardal and Shiva Subramanian, Biopeak positions itself at the intersection of diagnostics, technology, and preventive medicine. The startup focuses on improving healthspan by identifying risks early and intervening before chronic conditions take hold.
Biopeak describes its approach as a “family health office” model. Instead of reacting to illness, the platform emphasises continuous monitoring, personalised insights, and lifestyle-based interventions.
Deep Diagnostics at the Core
At the heart of Biopeak’s offering is an extensive diagnostic stack. The platform profiles over 130 biomarkers using a combination of blood tests, genetic and epigenetic analysis, microbiome mapping, hormonal assessments, salivary cortisol rhythms, and whole-exome functional genomics.
These insights are paired with high-resolution imaging, including MRI, CT, DXA, ECHO, and carotid IMT scans. Together, they allow Biopeak to track health changes over time and recommend targeted interventions across nutrition, sleep, stress, and overall lifestyle.
AI-Driven Personalisation
Biopeak uses AI-driven analytics to synthesise diagnostic data into personalised health plans. The goal is to detect potential risks early, measure progression with precision, and guide long-term behaviour change rather than short-term treatment.
The startup believes this data-led approach can help individuals extend not just lifespan, but quality of life.
Focus on South Asian Health Context
The Bengaluru-based company says it works closely with institutions such as IISc and Longevity India to adapt global health research to South Asian genetics, environmental factors, and lifestyle patterns.
This localisation, Biopeak argues, improves the relevance and accuracy of preventive care for Indian populations, which are often underrepresented in global health datasets.
Clinic Expansion Underway
Biopeak launched its first clinic in Bengaluru last year and plans to open another clinic in the city in the near term. The physical clinics serve as hubs for diagnostics, consultations, and long-term health tracking, complementing the company’s technology platform.
Investor Conviction in Preventive Health
NKSquared’s follow-on investment signals continued conviction in Biopeak’s longevity-led thesis. As healthcare shifts from reactive treatment to proactive prevention, investors are increasingly backing platforms that combine deep diagnostics, AI, and personalised care.
For Biopeak, the latest funding provides both capital and validation as it scales a model built around long-term health, not just short-term outcomes.
Follow us Instagram and stay updated with our current news
